Cite

    Schiff, M. et al. (2014). Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administration. Annals of the rheumatic diseases. 73 (8), pp. 1549-1551. [Online].